147 related articles for article (PubMed ID: 36029665)
21. High serum immunoglobulin D levels in systemic lupus erythematosus: more to be found?
Liang P; Huang Q; Xu Y; Chen L; Li J; Xu A; Yang Q
Clin Rheumatol; 2023 Apr; 42(4):1069-1076. PubMed ID: 36585530
[TBL] [Abstract][Full Text] [Related]
22. Serum cytokine levels associated with myocardial injury in systemic lupus erythematosus.
du Toit R; Reuter H; Walzl G; Snyders C; Chegou NN; Herbst PG; Doubell AF
Rheumatology (Oxford); 2021 Apr; 60(4):2010-2021. PubMed ID: 33221897
[TBL] [Abstract][Full Text] [Related]
23. [Serum interleukin-2 receptor
Tian JY; Zhang X; Cheng G; Liu QH; Wang SY; He J
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1083-1087. PubMed ID: 34916686
[TBL] [Abstract][Full Text] [Related]
24. Changes of Serum IL-6, IL-17, and Complements in Systemic Lupus Erythematosus Patients.
Tang Y; Tao H; Gong Y; Chen F; Li C; Yang X
J Interferon Cytokine Res; 2019 Jul; 39(7):410-415. PubMed ID: 31173544
[TBL] [Abstract][Full Text] [Related]
25. Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE.
Andersen LS; Petersen J; Svenson M; Bendtzen K
Autoimmunity; 1999; 30(4):235-42. PubMed ID: 10524499
[TBL] [Abstract][Full Text] [Related]
26. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus.
Park YB; Lee SK; Kim DS; Lee J; Lee CH; Song CH
Clin Exp Rheumatol; 1998; 16(3):283-8. PubMed ID: 9631750
[TBL] [Abstract][Full Text] [Related]
27. Cytokine Profiling in Chinese SLE Patients: Correlations with Renal Dysfunction.
Yan C; Yu L; Zhang XL; Shang JJ; Ren J; Fan J; Feng XQ; Zhang RW; Xia ZB; Duan XW
J Immunol Res; 2020; 2020():8146502. PubMed ID: 33134397
[TBL] [Abstract][Full Text] [Related]
28. Anti-GAPDH Autoantibody Is Associated with Increased Disease Activity and Intracranial Pressure in Systemic Lupus Erythematosus.
Sun J; Li X; Zhou H; Liu X; Jia J; Xie Q; Peng S; Sun X; Wang Q; Yi L
J Immunol Res; 2019; 2019():7430780. PubMed ID: 31049359
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-25 is upregulated in patients with systemic lupus erythematosus and ameliorates murine lupus by inhibiting inflammatory cytokine production.
Li Y; Wang R; Liu S; Liu J; Pan W; Li F; Li J; Meng D
Int Immunopharmacol; 2019 Sep; 74():105680. PubMed ID: 31200339
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients.
He D; Liu M; Liu B
Tohoku J Exp Med; 2018 Apr; 244(4):263-270. PubMed ID: 29576585
[TBL] [Abstract][Full Text] [Related]
31. Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus.
Brilland B; Bach-Bunner M; Gomes CN; Larochette V; Foucher E; Plaisance M; Saulnier P; Costedoat-Chalumeau N; Ghillani P; Belizna C; Delneste Y; Augusto JF; Jeannin P
Front Immunol; 2021; 12():663192. PubMed ID: 34054830
[TBL] [Abstract][Full Text] [Related]
32. Serum Interleukin-34 Levels Are Elevated in Patients with Systemic Lupus Erythematosus.
Wang H; Cao J; Lai X
Molecules; 2016 Dec; 22(1):. PubMed ID: 28036035
[TBL] [Abstract][Full Text] [Related]
33. Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.
Cai Z; Wong CK; Kam NW; Dong J; Jiao D; Chu M; Lam CW; Tam LS
Lupus; 2015 Oct; 24(12):1257-66. PubMed ID: 25966926
[TBL] [Abstract][Full Text] [Related]
34. Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis.
Adhya Z; El Anbari M; Anwar S; Mortimer A; Marr N; Karim MY
Lupus; 2019 May; 28(6):713-721. PubMed ID: 31046570
[TBL] [Abstract][Full Text] [Related]
35. Serum Amyloid A: A Potential Biomarker Assessing Disease Activity in Systemic Lupus Erythematosus.
Wang CM; Deng JH; Mao GF; He YL; Shi X
Med Sci Monit; 2020 Jun; 26():e923290. PubMed ID: 32584794
[TBL] [Abstract][Full Text] [Related]
36. Impact of IL-34, IFN-α and IFN-λ1 on activity of systemic lupus erythematosus in Egyptian patients.
Adel Y; Sadeq Y
Reumatologia; 2020; 58(4):221-230. PubMed ID: 32921829
[TBL] [Abstract][Full Text] [Related]
37. The Bladder Microbiome, Metabolome, Cytokines, and Phenotypes in Patients with Systemic Lupus Erythematosus.
Liu F; Du J; Zhai Q; Hu J; Miller AW; Ren T; Feng Y; Jiang P; Hu L; Sheng J; Gu C; Yan R; Lv L; Wolfe AJ; Feng N
Microbiol Spectr; 2022 Oct; 10(5):e0021222. PubMed ID: 35913213
[TBL] [Abstract][Full Text] [Related]
38. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
Wais T; Fierz W; Stoll T; Villiger PM
J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity.
Suzuki H; Takemura H; Kashiwagi H
Arthritis Rheum; 1995 Aug; 38(8):1055-9. PubMed ID: 7639800
[TBL] [Abstract][Full Text] [Related]
40. Elevated Layilin-Positive Monocyte Levels in the Peripheral Blood of Patients with Systemic Lupus Erythematosus Reflect Their Autoimmune Status.
Liu C; Wang Y; Zhang YH; Yuan Z; Zhang Z; Zeng X; Guan Z; Bahabayi A; Lu S
Immunol Invest; 2023 Nov; 52(7):879-896. PubMed ID: 37642473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
